A Cost-Effectiveness Analysis of Reslizumab in the Treatment of Poorly Controlled Eosinophilic Asthma.

CONCLUSIONS: The improvement in QoL and exacerbation rates with reslizumab are associated with high costs, making reslizumab unlikely to be cost-effective at the $200,000 WTP threshold. PMID: 30003833 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30003833?dopt=Abstract

Source: Journal of Asthma - July 15, 2018 Category: Respiratory Medicine Tags: J Asthma Source Type: research